Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-17-064325
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-12-07 09:57:51
Reporting Period:
2017-11-03
Accepted Time:
2017-12-07 09:57:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
816284 Celgene Corp /de/ 86 Morris Avenue
Summit NJ 07901
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-11-03 22,759 $19.10 4,812,221 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-06 79,327 $18.89 4,732,894 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-07 23,000 $18.54 4,709,894 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-08 16,875 $18.06 4,693,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-09 20,000 $17.08 4,673,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-10 10,000 $17.28 4,663,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-13 65,093 $17.76 4,597,926 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-14 14,907 $17.19 4,583,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-15 15,000 $17.67 4,568,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-16 105,000 $18.39 4,463,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-17 51,282 $18.44 4,411,737 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-20 158,718 $19.02 4,253,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2018-11-21 80,000 $19.25 4,173,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-22 256,000 $19.76 3,917,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-24 26,010 $20.00 3,891,009 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-27 27,990 $19.75 3,863,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-28 5,080 $19.22 3,857,939 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-29 4,263 $19.25 3,853,676 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-11-30 12,666 $19.04 3,841,010 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-12-01 87,991 $19.10 3,753,019 No 4 S Indirect See explanation of responses
Common Stock Disposition 2017-12-04 30,485 $19.47 3,722,534 No 4 S Indirect See explanation of responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
No 4 S Indirect See explanation of responses
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $19.00 to $19.30 on 11/3/2017; $18.75 to $19.23 on 11/6/2017; $18.02 to $18.87 on 11/7/2017; $17.93 to $18.35 on 11/8/2017; $17.00 to $17.50 on 11/9/2017; $17.10 to $17.46 on 11/10/2017; $17.50 to $17.99 on 11/13/2017; $17.03 to $17.45 on 11/14/2017; $17.55 to $17.75 on 11/15/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4
  2. These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities.
  3. Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.